Cellular Biomedicine Group's Stock Price Quadruples In Two Months

August 15, 2014 -- On Monday, August 18, Dr. William Cao, CEO of Cellular Biomedicine Group will ring the closing bell at NASDAQ to celebrate CBMG's recent listing on the exchange. CBMG is a US-headquartered biotech that is developing new treatments for degenerative diseases and cancer in China. The NASDAQ event caps a busy two months for CBMG. During that time, the company reported positive data from a trial of its knee arthritis treatment, jettisoned its consulting business, raised $10 million in a private placement, paid $23 million to acquire a China cellular products company – and the company's stock price rose from below $6 to $23.

Help employers find you! Check out all the jobs and post your resume.